Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with significant insulin resistance and increased risk of cardiovascular disease. .Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been shown to inhibit Nieman...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
2010-08.
|
| Subjects: | |
| Online Access: | Get fulltext |